News Related to Jazz

Related coverage linked through entity extraction aliases.

ALX Oncology Reports 2025 Results, Advances Evorpacept and ALX2004 Clinical Programs

Feb 27, 2026

ALX Oncology reported fourth quarter and full year 2025 financial results, highlighting validation of CD47 as a predictive biomarker for evorpacept in HER2-positive cancers and progress in its ALX2004 EGFR-targeted ADC program.

Ligand Pharmaceuticals to Report Q4 and Full Year 2025 Results Amid Share Price Volatility

Feb 12, 2026

Ligand Pharmaceuticals will release Q4 and full year 2025 financial results on February 26, 2026, following recent share price declines despite strong annual returns. The company reported annual revenue of $251.233 million and net income of $48.581 million.